Logo

Apellis and Beam Sign a Five-Year Research Collaboration to Discover Novel Therapies for Complement-Driven Diseases

Share this
Apellis and Beam Sign a Five-Year Research Collaboration to Discover Novel Therapies for Complement-Driven Diseases

Apellis and Beam Sign a Five-Year Research Collaboration to Discover Novel Therapies for Complement-Driven Diseases

Shots:

  • Beam to receive $50M up front and $25M as near-term milestones & will be eligible to receive other milestones along with royalties on sales- following the exercise of the option. The companies will work on 6 research programs focusing on C3 & other complement targets in the eye- liver- and brain
  • Apellis holds exclusive rights to license each of the 6 programs & responsible for subsequent development. Beam may elect to enter a 50-50 co-development & co-commercialization agreement with Apellis for one of the programs licensed under the collaboration
  • Beam will utilize its base editing technology and conduct preclinical research on up to 6 base editing programs. The companies can extend the collaboration up to 2yrs. on a per year and program-by-program basis

Ref: Apellis | Image: Apellis

Click here to­ read the full press release 

Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions